首页> 外国专利> New hydrazide derivatives useful for treating or preventing disorders of lipid metabolism and cardiovascular disorders e.g. atherosclerosis, obesity, cerebral ischemia, type II diabetes and dyslipoproteinemia

New hydrazide derivatives useful for treating or preventing disorders of lipid metabolism and cardiovascular disorders e.g. atherosclerosis, obesity, cerebral ischemia, type II diabetes and dyslipoproteinemia

机译:可用于治疗或预防脂质代谢和心血管疾病的新酰肼衍生物。动脉粥样硬化,肥胖症,脑缺血,II型糖尿病和血脂异常

摘要

Hydrazide derivatives (I) and their acid addition salts are new. Hydrazide derivatives of formula (I) and their acid addition salts are new. R 1, R 2H, 1-6C alkyl or 1-6C tri- to hepta-fluoroalkyl; A : mono- or poly-cyclic aryl or heteroaryl; B : optionally substituted phenyl. [Image] ACTIVITY : Antilipemic; Antiarteriosclerotic; Vasotropic; Anorectic; Antidiabetic; Cerebroprotective; Hepatotropic. 2-Cyclopropyl-4-quinolinecarboxylic acid (2-hydroxy-4,6-dimethoxybenzylidene)hydrazide (Ia) gave 81% inhibition of lipoprotein (LDLox; not defined) accumulation in THP1 cells at a concentration of 2.5 mu M. MECHANISM OF ACTION : None given.
机译:酰肼衍生物(I)及其酸加成盐是新的。式(I)的酰肼衍生物及其酸加成盐是新的。 R 1>,R 2> H,1-6C烷基或1-6C三至七氟烷基; A:单环或多环芳基或杂芳基; B:任选取代的苯基。活动:抗血脂;抗动脉硬化;变压性厌食的;抗糖尿病脑保护肝的。 2-环丙基-4-喹啉羧酸(2-羟基-4,6-二甲氧基亚苄基)酰肼(Ia)在2.5μM的浓度下抑制了THP1细胞中脂蛋白(LDLox;未定义)的积累,抑制作用为81%。 :未给出。

著录项

  • 公开/公告号FR2865732A1

    专利类型

  • 公开/公告日2005-08-05

    原文格式PDF

  • 申请/专利权人 CLINIGENETICS;

    申请/专利号FR20040000913

  • 发明设计人 MARGUERIE GERARD;MALAUD ERIC;

    申请日2004-01-30

  • 分类号C07D333/70;C07D307/54;C07D333/38;C07D307/68;C07D209/18;C07D281/10;C07D407/12;C07D215/52;C07D209/86;C07C243/18;C07C311/16;A61K31/381;A61K31/341;A61K31/404;A61K31/554;A61K31/4155;A61K31/47;A61K31/403;A61K31/15;A61K31/18;A61P9/00;

  • 国家 FR

  • 入库时间 2022-08-21 21:58:18

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号